{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Busse A"],"pubmed_abstract":["<h4>Background</h4>Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or mutations of the WT1 epitope or epitope flanking sequences that may abolish proper T cell recognition or epitope presentation.<h4>Methods</h4>All patients had been enrolled in a WT1 peptide phase II vaccination trial (NCT00153582) and ultimately progressed despite induction of a WT1 specific T cell response. Blood and bone marrow samples prior to vaccination and during progression were analyzed for mRNA expression level of WT1. Base exchanges within the epitope sequence or flanking regions (10 amino acids N- and C-terminal of the epitope) were assessed with melting "],"journal":["Journal of translational medicine"],"pagination":["5"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2844374"],"repository":["biostudies-literature"],"pubmed_title":["Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination."],"pmcid":["PMC2844374"],"pubmed_authors":["Keilholz U","Nonnenmacher A","Ochsenreither S","Scheibenbogen C","Thiel E","Letsch A","Busse A"],"additional_accession":[]},"is_claimable":false,"name":"Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.","description":"<h4>Background</h4>Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or mutations of the WT1 epitope or epitope flanking sequences that may abolish proper T cell recognition or epitope presentation.<h4>Methods</h4>All patients had been enrolled in a WT1 peptide phase II vaccination trial (NCT00153582) and ultimately progressed despite induction of a WT1 specific T cell response. Blood and bone marrow samples prior to vaccination and during progression were analyzed for mRNA expression level of WT1. Base exchanges within the epitope sequence or flanking regions (10 amino acids N- and C-terminal of the epitope) were assessed with melting ","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Jan","modification":"2025-04-25T17:01:26.382Z","creation":"2019-03-27T00:29:39Z"},"accession":"S-EPMC2844374","cross_references":{"pubmed":["20092642"],"doi":["10.1186/1479-5876-8-5"]}}